Sulfur, Selenium Or Tellurium Compound (e.g., Thioalcohols, Mercaptans, Etc.) Patents (Class 514/706)
  • Patent number: 6432434
    Abstract: The administration of &agr;-lipoic acid (&agr;LA) and dihydrolipoic acid (DHL) both as a preventive measure before exposure to conditions which may cause damage, such as rapid changes in atmospheric pressure, and as a means of preventing or ameliorating damage arising from such injury provides benefits not currently available. The active agents may be administered systemically or to the injured tissue. For example, when there is spinal cord injury, the active agents may be administered intrathecally.
    Type: Grant
    Filed: April 21, 2000
    Date of Patent: August 13, 2002
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: James L. Meyerhoff, Joseph Long, Michael Koenig
  • Patent number: 6433023
    Abstract: This invention is directed to a composition comprising 4-chloro-3,6-dinitrobenzotrifluoride and related compounds and method for using it to treat infections caused by organisms that have microtubules.
    Type: Grant
    Filed: March 26, 1998
    Date of Patent: August 13, 2002
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Heather Callahan, Colleen Kelley, Max Grogl, Brian G. Schuster
  • Publication number: 20020107176
    Abstract: Novel brain targeted low molecular weight, hydrophobic antioxidants and use of antioxidants in treatment of central nervous system neurodegenerative disorders such as Parkinson's, Alzheimer's and Creutzfeldt-Jakob's diseases and in treatment of conditions of peripheral tissues, such as acute respiratory distress syndrome, amyotrophic lateral sclerosis, atheroscierotic cardiovascular disease and multiple organ dysfunction, in which oxidants are overproduced.
    Type: Application
    Filed: April 3, 2002
    Publication date: August 8, 2002
    Inventors: Daphne Atlas, Eldad Melamed, Daniel Offen
  • Patent number: 6426370
    Abstract: The invention relates to the use of thiol compounds in viral inactivation in a cell-free environment, especially in the blood, blood plasma, blood serum, conserved blood, blood products, cell culture liquids and nutrient media and to the application of said compounds on the surface of plants and animals. Viral inactivation occurs without requiring cell metabolism.
    Type: Grant
    Filed: April 19, 2000
    Date of Patent: July 30, 2002
    Inventor: Peter Hofschneider
  • Patent number: 6423349
    Abstract: Compositions comprising glutamine in combination with other nutrients, including N-acetyl-cysteine and Vitamins A, C, E are disclosed. Such compositions can be administered for promoting recovery in patients undergoing elective surgery and for treating multiple organ system failure.
    Type: Grant
    Filed: August 24, 2000
    Date of Patent: July 23, 2002
    Assignee: Baxter International, Inc.
    Inventors: J. Dale Sherratt, Joann Somerville
  • Publication number: 20020068765
    Abstract: This invention describes the new benzocycloheptenes of general formula I 1
    Type: Application
    Filed: July 19, 1999
    Publication date: June 6, 2002
    Inventors: ROLF BOHLMANN, JORG KROLL, HERMANN KUENZER, CHRISTA HEGELE-HARTUNG, MONIKA LESSL, ROSEMARIE LICHTNER, YUKISHIGE NISHINO
  • Patent number: 6399106
    Abstract: A method for maintaining the freshness of a cut flower is disclosed. The method comprises the step of causing a flowering plant to imbibe an aqueous solution of a composition for maintaining the freshness of flower which comprises a mixture or a reaction product of a silver compound and an organic compound having a functional group capable of forming a water-soluble complex with a silver ion through the sulfur atom thereof to a flowering plant.
    Type: Grant
    Filed: June 9, 1998
    Date of Patent: June 4, 2002
    Assignee: Konica Corporation
    Inventor: Masahiko Yamasaki
  • Patent number: 6395781
    Abstract: 20-HETE agonists and antagonists are disclosed along with therapeutic applications. In a preferable form of the invention, the 20-HETE agonists are selected from the group consisting of 21-hydroxyheneicosa-5(Z),8(Z),11(Z),14(Z)-tetraenoic acid, 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid and 20-,21-dimethyl 20-HETE. Preferable 20-HETE antagonists include 5(S)-HETE, 15(S)-HETE, 19(S)-HETE, 19-hydroxynonadeca-5(Z),8(Z),11(Z),14(Z)-tetraenoic acid and 20-hydroxyeicosa 6(Z),15(Z)-dienoic acid.
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: May 28, 2002
    Assignee: MCW Research Foundation
    Inventors: Richard J. Roman, John R. Falck, Magdalena Alonso-Galicia, Elizabeth R. Jacobs, David R. Harder
  • Patent number: 6387412
    Abstract: A storage stable magnesium oxychloride coated granular animal feed mineral supplement composition resistant to disintegration cause by moisture absorption and attrition, comprising granular mineral nutrients useful as animal feed supplements and magnesium oxychloride coatings amounting to between 0.5 and 10.0 percent of the weight of the granules, formed on the granules of mineral nutrients by coreaction of magnesium chloride and magnesium oxide. An additional coating of between 0.2 and 2.0 percent magnesium stearate formed on the magnesium oxychloride may be used to decrease the rate of wetting of the granular animal feed mineral supplements.
    Type: Grant
    Filed: April 14, 2000
    Date of Patent: May 14, 2002
    Assignee: Agri-Nutrients Technology Group, Inc.
    Inventor: William P. Moore
  • Publication number: 20020049244
    Abstract: 20-HETE agonists and antagonists are disclosed along with therapeutic applications. In a preferable form of the invention, the 20-HETE agonists are selected from the group consisting of 21-hydroxyheneicosa-5(Z), 8(Z),11(Z),14(Z)-tetraenoic acid, 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid and 20-,21-dimethyl 20-HETE. Preferable 20-HETE antagonists include 5(S)-HETE, 15(S)-HETE, 19(S)-HETE, 19-hydroxynonadeca-5(Z),8(Z),11(Z),14(Z)-tetraenoic acid and 20-hydroxyeicosa 6(Z),15(Z)-dienoic acid.
    Type: Application
    Filed: December 14, 2001
    Publication date: April 25, 2002
    Inventors: Richard J. Roman, John R. Falck, Magdalena Alonso-Galicia, Elizabeth R. Jacobs, David R. Harder
  • Publication number: 20020037881
    Abstract: Omega chain modified 15-HETE derivatives and methods of their use for treating dry eye are disclosed.
    Type: Application
    Filed: September 20, 2001
    Publication date: March 28, 2002
    Inventor: David B. Belanger
  • Patent number: 6355690
    Abstract: To elucidate the molecular mechanisms of “gain of toxic function” of expanded polyglutamine stretches in CAG repeat expansion diseases, the inventors established an expression system of full-length and truncated cDNAs for dentatorubral-pallidoluysian atrophy (DRPLA) and found that truncated DRPLA proteins containing the expanded polyglutamine stretch, but not the full-length protein, form peri- and intra-nuclear aggregates consisting of filaments and concomitant apoptosis. The apoptotic cell death was partially suppressed by transglutaminase inhibitors, cystamine and monodansyl cadaverine, raising the possibility of involvement of transglutaminase reaction. The results may provide a potential basis for the development of therapeutic measures for CAG repeat expansion diseases.
    Type: Grant
    Filed: January 22, 1999
    Date of Patent: March 12, 2002
    Assignee: Niigata University
    Inventor: Shoji Tsuji
  • Patent number: 6344485
    Abstract: Methods of using prostaglandin agonists for the reduction of intraocular pressure, and accordingly glaucoma.
    Type: Grant
    Filed: June 18, 1999
    Date of Patent: February 5, 2002
    Assignee: Pfizer Inc.
    Inventors: Kimberly O. Cameron, Bruce A. Lefker
  • Patent number: 6342499
    Abstract: The present invention provides a method to control parasitic and saprophagous mites on beneficial insects such as honeybees via the application of a parasiticidally or saprophagouscidally effective amount of a mitochondrial electron transport inhibitor or a pyrimidine compound of formula I.
    Type: Grant
    Filed: July 12, 1999
    Date of Patent: January 29, 2002
    Assignee: BASF Aktiengesellschaft
    Inventors: Bruce Christian Black, William R. Baumbach, Michael P. Beluch
  • Patent number: 6307101
    Abstract: Disclosed are novel inhibitors of metalloproteases, in particular matrix metalloproteases. The disclosed inhibitors are mercaptoketone and mercaptoalcohol compounds which are useful in pharmaceutical compositions and methods for treating or controlling disease states or conditions which involve tissue breakdown, for example, arthropathy, dermatological conditions, bone resorption, inflammatory diseases, and tumor invasion and in the promotion of wound healing.
    Type: Grant
    Filed: March 17, 1999
    Date of Patent: October 23, 2001
    Inventors: David A. Campbell, Dinesh V. Patel, Xiao-Yi Xiao
  • Patent number: 6297289
    Abstract: Substances, methods and devices for moisturizing the eye by stimulation of the lachrymatory glands to cause generation of tears.
    Type: Grant
    Filed: May 7, 2001
    Date of Patent: October 2, 2001
    Assignee: Belmar Corporation
    Inventor: Elliott J. Siff
  • Patent number: 6291441
    Abstract: This invention relates to a method of treating patients suffering from the inflammatory bowel disorders. The method includes administering to a patient in need of treatment an effective amount of a thiol or reducible disulfide compound according to the formula set forth in the specification.
    Type: Grant
    Filed: September 27, 2000
    Date of Patent: September 18, 2001
    Inventors: Frederick H. Hausheer, Seetharamulu Peddaiahgari
  • Patent number: 6290937
    Abstract: Disclosed are methods and compositions for regulating the melanin content of mammalian melanocytes; regulating pigmentation in mammalian skin, hair, wool or fur; treating or preventing various skin and proliferative disorders; by administration of various compounds, including alcohols, diols and/or triols and their analogues.
    Type: Grant
    Filed: May 28, 1998
    Date of Patent: September 18, 2001
    Assignee: Applied Genetics Incorporated Dermatics
    Inventors: David A. Brown, Alexander A. Khorlin, Krystyna Lesiak, Wu Yun Ren
  • Publication number: 20010016606
    Abstract: Substances, methods and devices for moisturizing the eye by stimulation of the lachrymatory glands to cause generation of tears.
    Type: Application
    Filed: May 7, 2001
    Publication date: August 23, 2001
    Inventor: Elliott J. Siff
  • Patent number: 6274627
    Abstract: In accordance with the present invention, there are provided conjugates of physiologically compatible free radical scavengers (e.g., dithiocarbamate disulfides (DD)) and pharmacologically active agents (e.g., NSAIDS). Invention conjugates provide a new class of pharmacologically active agents (e.g., anti-inflammatory agents) which cause a much lower incidence of side-effects due to the protective effects imparted by modifying the pharmacologically active agents as described herein. In addition, invention conjugates are more effective than unmodified pharmacologically active agents because cells and tissues contacted by the pharmacologically active agent(s) are protected from the potentially damaging effects of free radical overproduction induced thereby as a result of the co-production of free radical scavenger (e.g., dithiocarbamate), in addition to free pharmacologically active agent, when invention conjugate is cleaved.
    Type: Grant
    Filed: October 12, 1999
    Date of Patent: August 14, 2001
    Assignee: Medinox, Inc.
    Inventors: Ching-San Lai, Vassil P. Vassilev, Tingmin Wang
  • Patent number: 6267952
    Abstract: The invention features a method for treating obesity in a patient by administering to the patient a polymer that has been substituted with one or more groups that inhibit lipases, which are enzymes responsible for the hydrolysis of fat. The invention further relates to the polymers employed in the methods described herein as well as novel intermediates and methods for preparing the polymers.
    Type: Grant
    Filed: October 5, 1998
    Date of Patent: July 31, 2001
    Assignee: GelTex Pharmaceuticals, Inc.
    Inventors: W. Harry Mandeville, III, Molly Kate Boie, Venkata R. Garigapati
  • Patent number: 6255277
    Abstract: A method for preventing adverse effects associated with the use of a medical device in a patient by introducing into the patient a device of which at least a portion includes a prophylactic or therapeutic amount of a nitric oxide adduct. The nitric oxide adduct can be present in a matrix coating on a surface of the medical device; can be coated per se on a surface of the medical device; can be directly or indirectly bound to reactive sites on a surface of the medical device; or at least a portion of the medical device can be formed of a material, such as a polymer, which includes the nitric oxide adduct. Also disclosed is a method for preventing adverse effects associated with the use of a medical device in a patient by introducing the device during a medical procedure and before or during said procedure locally administering a nitric oxide adduct to the site of contact of said device with any internal tissue.
    Type: Grant
    Filed: May 10, 1995
    Date of Patent: July 3, 2001
    Assignees: Brigham and Women's Hospital, NitroMed, Inc.
    Inventors: Jonathan Stamler, Joseph Loscalzo, John D. Folts
  • Patent number: 6255355
    Abstract: This invention relates to a method of treating patients in need of angiogenesis inhibition. The method includes administering to a patient in need of treatment an effective amount of a thiol or reducible disulfide compound according to the formula set forth in the specification.
    Type: Grant
    Filed: January 6, 2001
    Date of Patent: July 3, 2001
    Inventor: Seetharamulu Peddaiahgari
  • Patent number: 6255350
    Abstract: This invention relates to a single phase emulsifiable concentrate composition comprising (a) between about 0.05 and about 25 wt. % of a biologically, fungicidally and/or herbicidally active aza compound; (b) between about 2 and about 40 wt. % of a lactam selected from the group of N-methyl pyrrolidone, N-methyl caprolactam, a C8 to C18 alkyl pyrrolidone, a C8 to C18 caprolactam and a mixture thereof; (c) between about 2 and about 20 wt. % of a moisture scavenging agent selected from the group consisting of a liquid molecularly hindered carbodiimide, a molecular sieve or a mixture thereof and (d) between about 10 and about 80 wt. % of a mixture of at least two non-ionic surfactants having an overall hydrophilic/lipophilic balance (HLB) above 7. The invention also relates to the stable oil-in-water (o/w) miniemulsions prepared from the above by dilution to between about 40 and about 99.99 wt. % water for a “pour on”, dip or spray solution useful in the treatment of animals or plants.
    Type: Grant
    Filed: October 9, 1998
    Date of Patent: July 3, 2001
    Assignee: ISP Investments Inc.
    Inventors: Domingo I. Jon, Donald I. Prettypaul, Matthew J. Benning, Kolazi S. Narayanan, Robert M. Ianniello
  • Patent number: 6251952
    Abstract: Substances, methods and devices for moisturizing the eye by stimulation of the lachrymatory glands to cause generation of tears.
    Type: Grant
    Filed: December 9, 1993
    Date of Patent: June 26, 2001
    Assignee: Belmar Corporation
    Inventor: Elliott Justin Siff
  • Patent number: 6248371
    Abstract: Methods for administering a composition comprising bismuth and a thiol-containing complexing agent as a bacteriocidal, bacteriostatic, antifungal or antiviral agent are provided.
    Type: Grant
    Filed: April 6, 2000
    Date of Patent: June 19, 2001
    Assignee: Winthrop University Hospital
    Inventor: Philip Domenico
  • Patent number: 6242009
    Abstract: Microbicidal formulations are described which are preferably ecologically friendly and non-toxic to mammals, and are highly effective against a broad spectrum of detrimental pathogenic microorganisms. The microbicidal formulation contains complexes having the formula R-M, wherein R is at least one organic chelating moiety and M is at least one metal ion which is microbicidal to at least one microorganism. These complexes can disrupt microorganism activities by penetrating the natural protecting bio-films of such microorganisms through the reaction of the R-group with the organic constituents of these microorganisms while releasing M into their intra-cellular media. Thus, this process exhibits its biocidal activities from the inside-out, contrary to other methods which rely on damaging the protective biofilms.
    Type: Grant
    Filed: April 20, 1999
    Date of Patent: June 5, 2001
    Inventors: Kareem I. Batarseh, Marwan Al-Kayed
  • Patent number: 6239111
    Abstract: The present invention discloses the use, in the manufacture of a preventive and therapeutic drug of a brain disease, of a compound represented by formula (1): CH2═CH—CH2—S(O)n—R  (1) [wherein R represents a hydrogen atom, an alkyl group, an alkenyl group, a substituted alkyl group, a substituted alkenyl group, an alkylthio group, an alkenylthio group, a phenyl group, a substituted phenyl group, a heterocyclic group, or a group derived from an amino acid or an oligopeptide by deletion of one hydrogen atom, and which group may have a protective group; and n is 0, 1, or 2], a glycoside thereof, or a salt of the compound or the glycoside. The drug of the present invention for ameliorating brain diseases, inhibiting reduction of brain neurons and promoting branching of neurites, is useful for the prevention and treatment of brain diseases such as dementia in association with degeneration and sloughing of brain neurons.
    Type: Grant
    Filed: January 26, 1998
    Date of Patent: May 29, 2001
    Assignee: Wakunaga Pharmaceutical Co., Ltd.
    Inventors: Toru Moriguchi, Hiromichi Matsuura, Hiroshi Saito
  • Patent number: 6217914
    Abstract: An ascorbic acid-based composition and related method for the treatment of aging or photo-damaged skin is disclosed. The composition includes water and ascorbic acid, at least a portion of which has generally been pretreated by being dissolved under relatively high temperature and concentration conditions. The composition typically includes at least about 5.0% (w/v) ascorbic acid and may advantageously be formulated to have a pH above 3.5. Generally, the composition also includes non-toxic zinc salt, tyrosine compound, and/or pharmaceutically acceptable carrier. In addition, the composition may include an anti-inflammatory compound, such as aminosugar and/or sulfur-containing anti-inflammatory compound. The topical composition may be in the form of a serum, a hydrophilic lotion, an ointment, a cream, or a gel.
    Type: Grant
    Filed: July 19, 1999
    Date of Patent: April 17, 2001
    Assignee: Bioderm, Inc.
    Inventor: Lorraine Faxon Meisner
  • Patent number: 6197831
    Abstract: This invention relates to a method of treating patients afflicted with septic shock. The method includes administering to a patient in need of treatment an effective amount of a thiol or reducible disulfide compound according to the formula set forth in the specification.
    Type: Grant
    Filed: February 9, 1999
    Date of Patent: March 6, 2001
    Assignee: BioNumerik Pharmaceuticals, Inc.
    Inventor: Frederick Herman Hausheer
  • Patent number: 6177473
    Abstract: This invention is directed to benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives which are useful as anti-coagulants. This invention is also directed to pharmaceutical compositions containing the compounds of the invention, and methods of using the compounds to treat disease-states characterized by thrombotic activity.
    Type: Grant
    Filed: November 12, 1999
    Date of Patent: January 23, 2001
    Assignee: Berlex Laboratories, Inc.
    Inventors: Monica Kochanny, Michael M. Morrissey, Howard P. Ng
  • Patent number: 6177475
    Abstract: The invention provides methods of treating inflammatory diseases and conditions by administering an effective amount of an integrin modulating agent, as further defined and specified herein, to an animal suffering from one of the diseases or conditions. The preferred integrin modulating agents are ajoene and disintegrins, variants and analogs of disintegrins.
    Type: Grant
    Filed: May 12, 1997
    Date of Patent: January 23, 2001
    Assignee: Billings Pharmaceuticals, Inc.
    Inventors: Alexander V. Tatarintsev, Ali S. Turgiev, John B. Davidson
  • Patent number: 6149925
    Abstract: The invention provides cosmetic or pharmaceutical compositions for topical application to the skin comprising glutathione-enhancing effective amounts of a glycine compound, a glutamine compound, and a sulfhydryl-containing organic acid, in a cosmetically or pharmaceutically acceptable carrier. The compositions are useful in increasing glutathione synthesis in skin cells, and in treating skin conditions associated with glutathione depletion in skin cells.
    Type: Grant
    Filed: November 5, 1998
    Date of Patent: November 21, 2000
    Assignee: Color access, Inc.
    Inventors: Thomas Mammone, David C. Gan
  • Patent number: 6130244
    Abstract: In its broadest aspect, the present invention is directed to the discovery of immunonutritional products that are useful in reducing the immunological system suppression that results from stress. The stress may be in the form of physical exertion, mental exhaustion, disease states and the like. In one embodiment, the invention relates to a nutritional composition comprising a structured glyceride component and an antioxidant system. This nutritional composition has been shown to be highly effective in reducing immune system down regulation or dysregulation as a result of stress.
    Type: Grant
    Filed: February 25, 1998
    Date of Patent: October 10, 2000
    Assignee: Abbott Laboratories
    Inventors: Stephen J. DeMichele, Steven M. Wood
  • Patent number: 6127354
    Abstract: Novel peptide derivatives, compositions containing them, and their use for treating medical disorders resulting from a deficiency in growth hormone are disclosed. The peptides have the formula (I): ##STR1## wherein a, b, A, R.sup.1, L.sup.1, D, R.sup.3, R.sup.4, R.sup.2, L.sup.2, E and G are as defined in the specification. These peptides exhibit improved resistance to proteolytic degradation, and hence, improved bioavailability.
    Type: Grant
    Filed: March 17, 1999
    Date of Patent: October 3, 2000
    Assignee: Novo Nordisk A/S
    Inventors: Bernd Peschke, Michael Ankersen, Thomas Kruse Hansen, Henning Th.o slashed.gersen
  • Patent number: 6106821
    Abstract: The invention relates to fly attractant compositions that comprise at least one volatile short chain carboxylic acid, at least one organic sulfide and at least one nitrogen heterocycle. In a preferred embodiment the composition additionally comprises at least one ammonia-releasing compound. In a particularly preferred example, the composition is preparable by combining, for example, the carboxylic acid, the organic sulfide and the nitrogen heterocycle. The invention also relates to an insect trap comprising a means for retaining flies and an insect attractant composition of this invention. The trap is useful in commercial, residential and livestock facilities.
    Type: Grant
    Filed: December 5, 1997
    Date of Patent: August 22, 2000
    Assignee: Iowa State University Research Foundation, Inc.
    Inventors: Thomas C. Baker, Allard A. Cosse
  • Patent number: 6093411
    Abstract: The present invention relates to compositions for preventing or treating skin disorders using flavonoid compounds. The present invention also relates to methods for regulating skin condition.
    Type: Grant
    Filed: March 12, 1999
    Date of Patent: July 25, 2000
    Assignee: The Procter & Gamble Company
    Inventor: Donald Lynn Bissett
  • Patent number: 6093743
    Abstract: The present invention provides a novel dithiocarbamate disulfide dimer useful in various therapeutic treatments, either alone or in combination with other active agents. In one method, the disulfide derivative of a dithiocarbamate is coadministered with an agent that inactivates (or inhibits the production of) species that induce the expression of nitric oxide synthase to reduce the production of such species, while, at the same time reducing nitric oxide levels in the subject. In another embodiment, free iron ion levels are reduced in a subject by administration of a disulfide derivative of a dithiocarbamate(s) to scavenge free iron ions, for example, in subjects undergoing anthracycline chemotherapy. In another embodiment, cyanide levels are reduced in a subject by administration of a disulfide derivative of a dithiocarbamate so as to bind cyanide in the subject. In a further aspect, the present invention relates to compositions and formulations useful in such therapeutic methods.
    Type: Grant
    Filed: June 23, 1998
    Date of Patent: July 25, 2000
    Assignee: Medinox Inc.
    Inventors: Ching-San Lai, Vassil Vassilev
  • Patent number: 6086921
    Abstract: A composition described wherein bismuth is chelated by a complexing agent such as a pyrithione or certain other thiol compounds in the form a metal:complexing agent complex. Methods for using the composition as a bacteriocidal, bacteriostatic, antibiofilm, antifungal, and antiviral agent and as a disinfectant and preservative are also provided.
    Type: Grant
    Filed: October 28, 1997
    Date of Patent: July 11, 2000
    Assignee: Wintrop-University Hospital
    Inventor: Philip Domenico
  • Patent number: 6086789
    Abstract: A pyruvate compound suitable for cosmetically or dermatologically administering to the skin and for use in treating diabetic ketosis or other medical treatments. The compound includes a pyruvate selected from the group of pyruvate thioester, dihydroxyacetonepyruvate, and an ester of pyruvate and a sugar or a polyol.
    Type: Grant
    Filed: May 12, 1998
    Date of Patent: July 11, 2000
    Assignee: Case Western Reserve University
    Inventors: Henri Brunengraber, Catherine Bomont, France David, Peter T. Hallowell, Kevin D. Cooper, Takhar Kasoumov
  • Patent number: 6080417
    Abstract: The invention concerns a hand disinfectant based on lower alcohols and is characterized by an aqueous solution of lower alcohols with synergists, the solution having a flash point of more than 21.degree. C.
    Type: Grant
    Filed: August 31, 1998
    Date of Patent: June 27, 2000
    Assignee: Antiseptica Chemisch-Pharmazeutische Produkte GmbH
    Inventors: Axel Kramer, Leopold Dohner
  • Patent number: 6077838
    Abstract: This invention relates to a method of treating patients afflicted with hangover. The method includes administering to a patient in need of treatment an effective amount of a thiol or reducible disulfide compound according to the formula set forth in the specification.
    Type: Grant
    Filed: June 8, 1999
    Date of Patent: June 20, 2000
    Assignee: BioNumerik Pharmaceuticals, Inc.
    Inventor: Frederick Herman Hausheer
  • Patent number: 6075044
    Abstract: The use of certain heterocyclic derivatives for treating parasitic protozoa infections in mammals, in particular bovine trichomoniasis and giardiasis, is disclosed.
    Type: Grant
    Filed: July 17, 1998
    Date of Patent: June 13, 2000
    Assignee: The Regents of the University of California
    Inventors: Ching C. Wang, John Somoza, Jon P. Page, Ronaldus Marcellus Alphonsus Knegtel, Irwin D. Kuntz, Connie M. Oshiro, A. Geoffrey Skillman
  • Patent number: 6020382
    Abstract: The instant invention is concerned with acetylphenols which are useful as antiobesity and antidiabetic compounds. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering or modulating triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for increasing gut motility or for treating atherosclerosis are also disclosed.
    Type: Grant
    Filed: January 4, 1999
    Date of Patent: February 1, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Thomas W. Doebber, Joel P. Berger, Gregory D. Berger, Mark D. Leibowitz, David E. Moller, John T. Olson, Arthur A. Patchett, Richard B. Toupence
  • Patent number: 6004771
    Abstract: A method for the preparation of Mycobacteria from any liquid, semi solid or exotic source is described. The extracted Mycobacterial sample is suitable for detection by culture and amplification.
    Type: Grant
    Filed: August 11, 1997
    Date of Patent: December 21, 1999
    Assignee: Integrated Research Technology, LLC
    Inventor: Charles G. Thornton
  • Patent number: 5990169
    Abstract: Compounds containing two aromatic systems covalently linked through a linker containing one or more atoms, or "linker" defined as including a covalent bond per se so as to space the aromatic systems at a distance 1.5-15 .ANG., are effective in treating conditions associated with bone deficits. The compounds can be administered to vertebrate subjects alone or in combination with additional agents that promote bone growth or that inhibit bone resorption. They can be screened for activity prior to administration by assessing their ability to effect the transcription of a reporter gene coupled to a promoter associated with a bone morphogenetic protein and/or their ability to stimulate calvarial growth in model animal systems.
    Type: Grant
    Filed: February 26, 1997
    Date of Patent: November 23, 1999
    Assignees: ZymoGenetics, Inc., Osteoscreen, Inc.
    Inventors: Charles Petrie, Mark W. Orme, Nand Baindur, Kirk G. Robbins, Scott M. Harris, Gregory R. Mundy
  • Patent number: 5981602
    Abstract: The present invention relates to the use of ajoene for inhibiting integrin-mediated cell-cell fusion. Specific types of cell-cell fusion are giant multinucleated cell formation, syneytia formation, and osteoclast formation.
    Type: Grant
    Filed: January 11, 1996
    Date of Patent: November 9, 1999
    Assignee: John B. Davidson
    Inventors: Alexander V. Tatarintsev, Ali S. Turgiev, John B. Davidson
  • Patent number: 5972993
    Abstract: A method for treating skin conditions, such as rosacea and sensitive skin, that manifest as a tendency towards flushing and blushing is provided. Also provided herein, are compositions for the treatment of rosacea and sensitive skin that are comprised of at least one antioxidant selected from the following groups of antioxidants: (a) phenolic compounds that contain at least one hydroxyl group connected directly to a benzene ring and to another unsaturated chemical grouping, (b) sulfur-containing compounds that contain at least one sulfhydryl groups or sulfur-containing compounds that contain at least one disulfide group, or (c) polyene compounds that have conjugated systems of double bonds.
    Type: Grant
    Filed: March 20, 1998
    Date of Patent: October 26, 1999
    Assignee: Avon Products, Inc.
    Inventor: Dmitri Ptchelintsev
  • Patent number: 5973009
    Abstract: The objects of the present invention are:novel organoselenium compounds: aromatic diselenides and selenosulphides;the use of said novel compounds as antioxidant agents;pharmaceutical compositions containing them;a method of preparation of said novel compounds.
    Type: Grant
    Filed: December 23, 1997
    Date of Patent: October 26, 1999
    Assignee: Oxis International S.A.
    Inventors: Catherine Tailhan-Lomont, Irene Erdelmeier, Marc Moutet, Jean Chaudiere, Jean-Claude Yadan
  • Patent number: RE37793
    Abstract: A composition comprising a trivalent bismuth salt, particularly bismuth nitrate, and dimercaprol is described. Methods for using the composition as a bacteriocidal and bacteriostatic agent and as a disinfectant and preservative are also provided.
    Type: Grant
    Filed: October 13, 2000
    Date of Patent: July 16, 2002
    Assignee: Winthrop University Hospital
    Inventor: Philip Domenico